Q4 2025 Cipher Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Cipher Pharmaceuticals Inc (CPHRF) reported a significant increase in revenue and earnings for the fiscal year 2025, with revenue more than doubling compared to the previous year.
- The acquisition of the US-based Natroba business has been highly successful, contributing $30 million in sales for 2025, a substantial increase from $12 million in 2024.
- The Natroba business achieved a strong gross margin of 83% for the fiscal year 2025, driving an adjusted EBITDA of $17.4 million.
- Cipher Pharmaceuticals Inc (CPHRF) has made significant progress in deleveraging, reducing its revolving credit facility balance from $40 million to $5 million within 18 months.
- The company has launched a direct-to-consumer (DTC) sales model for Natroba, which is expected to enhance accessibility and potentially increase sales volumes.
- Cipher Pharmaceuticals Inc (CPHRF) experienced a decline in licensing revenue, with a decrease of $3 million in 2025 compared to 2024, primarily due to reduced revenue from the Absorica portfolio.
- The Absorica portfolio continues to face pressure from a highly competitive market saturated with generic competition, impacting sales and royalty revenue.
- The company's international out-licensing strategy for Natroba is taking longer than expected, with challenges in agreeing on product pricing with potential partners.
- Selling, general, and administrative expenses increased by 11% in 2025 compared to 2024, partly due to a full year of expenses from the acquired US business.
- Despite the launch of the DTC platform, it is still in its early stages, and its impact on sales growth remains uncertain.
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Cipher Pharmaceuticals quarterly conference call for the company's fourth quarter and full year 2025 results. (Operator Instructions) As a reminder, this conference is being recorded today, Friday, March 13, 2026. On behalf of the speakers that follow, listeners are cautioned that today's presentation and the responses to questions may contain forward-looking statements within the meaning of the safe harbor provisions of the Canadian provincial securities laws.
Forward-looking statements involve risks and uncertainties and undue reliance should not be placed on such statements. Certain material factors or assumptions are implied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements.
For additional information about factors that cause results to vary, please refer to the risks identified in the company's annual information form and other filings with Canadian regulatory authorities, except as required by Canadian securities laws. The
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
